Abstract: Some aspects of this disclosure provide methods and reagents for the detection of apolipoproteins in a sample, for example, a sample obtained from a human subject. Some aspects of this disclosure provide protocols and reagents for the quantification of lipoproteins and lipoprotein particle populations comprising specific combinations of non-integral apolipoproteins and integral apolipoproteins, which is useful, inter alia, for the detection of diseases such as cardiovascular disease as well as an assessment of the risk of an individual to develop a disease.

Abstract: Some aspects of this disclosure relate to the characterization of lipoproteins (e.g., vLDL, LDL, and/or HDL) based on their content of lipoprotein-associated proteins (e.g., apolipoproteins) for the determination of cardiovascular disease risk. Some aspects of this disclosure relate to methods for the diagnosis, early detection, risk estimation and monitoring of the course of diseases, in which one or more lipoprotein-associated protein is detected in a lipoprotein. The characterization of the levels of lipoproteins with different lipoprotein-associated protein content provide an index for assessing the risk of a disease, for example, a cardiovascular disease.

Abstract: Some aspects of this disclosure provide methods and reagents for the detection of apolipoproteins in a sample, for example, a sample obtained from a human subject. Some aspects of this disclosure provide protocols and reagents for the quantification of lipoproteins and lipoprotein particle populations comprising specific combinations of non-integral apolipoproteins and integral apolipoproteins, which is useful, inter alia, for the detection of diseases such as cardiovascular disease as well as an assessment of the risk of an individual to develop a disease.

Abstract: Presented herein are methods of diagnosing, assessing, and treating an individual at increased risk if developing coronary heart disease or cardiovascular event, based on the individual's level of high density lipoprotein cholesterol apoCIII (HDL-C apoCIII).

Abstract: Presented herein are methods of diagnosing, assessing, and treating an individual at increased risk if developing coronary heart disease or cardiovascular event, based on the individual's level of high density lipoprotein cholesterol apoCIII (HDL-C apoCIII).